AXGN:NASDAQ
AxoGen, Inc Common Stock
US$41.99
0.00%
(0.00) 1 天
US$41.31
arrow_downward
-1.62% (-0.68)today开盘前
休市： 4月28日, GMT-4 16:00:01 · USD
search
所有股票代码
1 天
5 天
1 个月
6 个月
年初至今
1 年
5 年
最大
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 AXGN 生成关键数据洞见…
市值
二一.七九亿
平均成交量
一〇七.五八万
成交量
一.五二万
52 周最高价
US$39.99
52 周最低价
US$9.22
每股收益
-US$0.34
Beta 版
〇.九八
流通股数
五一八九.八〇万
员工人数
六二二
新闻报道
来自全网
Investing.com
·
1小时前
H.C. Wainwright raises AxoGen stock price target to $50 on revenue beat
Simply Wall Street
·
11小时前
Axogen (AXGN) Q1 Loss Of US$0.38 EPS Tests Bullish Margin Improvement Narrative
资料
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use. Wikipedia
AxoGen, Inc Common Stock简介